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Summary
Background Chronic spontaneous urticaria (CSU) is a skin disease with itchy hives
and/or angio-oedema that last for at least 6 weeks without an obvious external
trigger.
Objectives To determine the cost-effectiveness of omalizumab relative to standard
of care (SoC; up to four times the daily dose of H1-antihistamines) in the
Netherlands from a societal perspective.
Methods The Markov model used consisted of five health states based on Urticaria
Activity Score over 7 days. Model settings and characteristics of the Dutch patient
population were based on an online survey among clinical experts and were vali-
dated during an expert committee meeting. Transition probabilities were derived
from the GLACIAL trial. Healthcare consumption, quality of life (using EuroQol-
5D) and productivity losses were derived from a burden-of-illness study
(ASSURE-CSU) among 93 Dutch patients. Healthcare consumption and productiv-
ity losses were evaluated using the Dutch costing manual. The comparator treat-
ment was SoC, consisting of (updosed) antihistamines. A 10-year time horizon
was used.
Results The incremental cost-effectiveness ratio (ICER) of omalizumab vs. SoC was
€17 502 per quality-adjusted life-year (QALY) gained. Productivity costs played
an important role in the value of the ICER; discarding productivity costs resulted
in an ICER of €85 310 per QALY.
Conclusions Omalizumab is cost-effective compared with SoC. The outcomes of this
study were used to establish omalizumab as third-line therapy in the Dutch treat-
ment guidelines for CSU.
What’s already known about this topic?
• Omalizumab is an effective treatment for chronic spontaneous urticaria, as it
reduces the clinical signs and symptoms.
• However, omalizumab is also more expensive than existing treatments.
What does this study add?
• Omalizumab is a cost-effective treatment option in chronic spontaneous urticaria in
the Dutch situation.
• Productivity costs have a large impact on the cost-effectiveness of omalizumab in
chronic spontaneous urticaria.
• Omalizumab has been added to the Dutch treatment guidelines, partly based on
the results from this study.
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Chronic spontaneous urticaria (CSU) is a debilitating inflam-
matory skin disease. Patients with CSU experience itchy hives,
angio-oedema or both, over a period of at least 6 weeks,
occurring without a specific external trigger.1 The prevalence
of CSU at any point in time is between 05% and 10% of the
population.2 Evidence suggests that 33–67% of patients expe-
rience weals and angio-oedema. Many patients have psychi-
atric comorbidities. Patients with CSU experience impaired
quality of life, and in addition patients’ performance at school
and work is affected.2,3 Finally, CSU has a large socioeco-
nomic impact, due to direct and indirect healthcare costs, and
costs related to productivity losses.2
International guidelines3 recommend modern H1-antihista-
mines at the licensed dose as the first-line therapy for CSU. If
patients remain symptomatic, second-line treatment consists of
updosed antihistamines (up to four times). Some patients also
receive leukotriene antagonists (LTRAs). Third-line treatment
consists of ciclosporin and omalizumab. Ciclosporin has been
shown to be an effective third-line treatment, but it is associ-
ated with potential side-effects.4 Compared with standard of
care (SoC) and placebo, omalizumab on top of SoC reduces
the clinical symptoms and signs of CSU.5–7 Omalizumab is an
add-on treatment; patients also receive updosed antihistamines
and LTRAs.
To oppose rising healthcare costs, healthcare authorities
increasingly use cost-effectiveness as a factor in reimbursement
decisions. A cost-effectiveness model was built to assess the
cost-effectiveness of omalizumab for use in the U.K.8 The
objective of this study was to determine the cost-effectiveness
of omalizumab compared with SoC, namely updosed antihis-
tamines, in the Netherlands from a societal perspective.
Materials and methods
A pharmacoeconomic model was developed for the U.K.8 The
model was adapted to the Dutch situation. Adaptations were
made on the basis of two factors: (i) to follow Dutch pharma-
coeconomic guidelines9 and (ii) to reflect the Dutch epidemi-
ology and patient population adequately. Adaptations to the
model were based on input from clinical experts. Firstly, they
were consulted through an online survey (n = 6). The experts
were asked to provide information on prevalence, treatment
patterns, disease and use of informal care. The results of this
survey were presented to the experts in a second survey round
to reach consensus. Secondly, experts were consulted during
an expert committee meeting (n = 6), during which the mod-
el’s settings were presented and validated by experts.
Furthermore, patient-level data were obtained from an
international burden-of-illness study (ASSURE-CSU).10–13
ASSURE-CSU comprised a cross-sectional patient survey and a
12-month retrospective medical chart review. Data on health-
care utilization, quality of life and productivity losses were
obtained from the ASSURE-CSU patient survey. Data on treat-
ment and healthcare utilization were retrieved from the
ASSURE-CSU medical chart review. Data were available for 93
Dutch patients.
Cost-effectiveness model
Treatment options
In this study, omalizumab on top of SoC was compared with
SoC and placebo. SoC consists of updosed antihistamines and/
or LTRAs. The dosage of omalizumab was 300 mg in all anal-
yses. Omalizumab is given subcutaneously.
Model structure
A Markov model was used in this study. The model diagram
is presented in Figure 1. Health states were based on Urticaria
Activity Score over 7 days (UAS7).14 The UAS7 score uses a
daily diary measuring itches and hives over a period of
7 days. The score is continuous, ranging from 0 to 42, but it
can be divided into categories to reflect different levels of dis-
ease activity.15 The model consisted of five health states: urti-
caria free (score of 0), well-controlled urticaria (1–6), mild
urticaria (7–15), moderate urticaria (16–27) and severe urti-
caria (28–42). Transition probabilities between health states
for both treatment arms were derived from the phase III GLA-
CIAL trial, which compared omalizumab with placebo in
patients with CSU for a 24-week trial period.6 Response data
were presented in the publication of the original U.K. model.8
Remission data were based on an overview paper by Beltrani,
which summarized remission rates based on a review of other
studies.16 A death state was included to model background
mortality. Utilities and costs were health state specific – health
states did not differ between treatments. Differences in costs
and effects resulted from different transition probabilities and
hence differences in time spent in a specific health state.
Model settings
Only patients with moderate (UAS7 = 16–27) or severe CSU
(UAS7 = 28–42) were included in the model. In the absence
of published data for the Netherlands, the baseline distribution
of patients over the moderate and severe health states was
based on estimates from clinical experts. According to their
estimates, 29% of the population had severe CSU at baseline,
while the remaining 71% started in the moderate health state.
According to the Dutch clinical experts, the average age of
their population was 36 years. The clinical experts reached
consensus about these model input values. These values were
included as baseline values in the model. Following Dutch
pharmacoeconomic guidelines, the societal perspective was
adopted in this study, therefore all costs and effects were
included no matter who bears them. The time horizon was set
at 10 years, which according to clinical experts would incor-
porate all costs and effects of therapy.
Outcomes
Effects were measured in quality-adjusted life-years (QALYs),
which is a measure that combines length of life and quality of
© 2018 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2018) 179, pp702–708
Cost-effectiveness of omalizumab in chronic spontaneous urticaria, T.A. Kanters et al. 703
life. CSU does not affect survival, so survival was equal for all
treatment options. Survival was based on overall survival in
the general population of the Netherlands and data were
derived from Statistics Netherlands.17 Quality of life was
expressed in utilities, which range from 0 (death) to 1 (per-
fect health). Utilities were derived from the EuroQol 5
Dimensions (EQ-5D; 3-level version). The EQ-5D was
included in the ASSURE-CSU study. The Dutch tariffs were
used to compute utilities.18
Costs
Following the taxonomy of Drummond et al.,19 three types of
costs were considered: (i) costs within the healthcare sector,
which, in this study, consisted of healthcare utilization costs;
(ii) patient and family costs, which consisted of informal care
costs in this study; and (iii) costs to other sectors, which con-
sisted of productivity costs in this study.
Healthcare utilization for the five health states in the model
was derived from the ASSURE-CSU study. These data were
confined to healthcare utilization related to CSU. Healthcare
utilization was evaluated using the Dutch costing manual20
(unit costs are shown in Table S1; see Supporting Information).
Healthcare utilization included outpatient visits, emergency
department visits, hospital admissions, general practitioner
visits and laboratory tests. Medication prices were derived from
medicijnkosten.nl, as recommended by the Dutch costing
manual. Costs for diagnostics were derived from the National
Health Care Authority.21 The price of omalizumab was provided
by the manufacturer. The costs of administration of
omalizumab were based on the Dutch tariff for a vaccination.
Treatment costs for omalizumab also included SoC costs, as
omalizumab is given in addition to SoC.
All clinical experts stated that no informal care was con-
sumed by patients with CSU. Therefore, no costs for informal
care were included in the model.
Lost productivity for the five health states was derived from
the ASSURE-CSU study, which included productivity losses
due to both absenteeism (reduced number of hours at work)
and presenteeism (reduced efficiency at work). Productivity
losses were evaluated using wages from the Dutch costing
manual.20 Above the age of 6525 years (the Dutch retirement
age in 2014), no productivity losses were incurred.
Statistical analyses
The model’s main outcome parameter was the incremental
cost-effectiveness ratio (ICER). The ICER was calculated by
dividing the incremental costs (the additional total costs of
omalizumab relative to the total costs of SoC) by the incre-
mental effects (the additional effects of omalizumab relative to
the effects of SoC), and was expressed as the cost per QALY
gained. Following Dutch pharmacoeconomic guidelines, costs
were discounted at a rate of 4%; the discount rate for effects
was 15%. Costs were expressed in 2014 euros. Inflation cor-
rection was applied when necessary using consumer price
indexes derived from Statistics Netherlands.22 All analyses
were performed in Microsoft Excel.
Sensitivity analyses
One-way sensitivity analyses were performed to test the influ-
ence of individual parameters on the ICER, by increasing and
decreasing parameter values by 20%. The influence of the fol-
lowing parameters was assessed: efficacy of omalizumab,
spontaneous remission hazard ratio, cumulative relapse,
Fig 1. Diagram of the cost-effectiveness model structure. All states can transition to death state. UAS7, Urticaria Activity Score over 7 days.
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dropout rate, discontinuation of omalizumab, costs of omal-
izumab, direct healthcare costs, utility values, percentage of
people employed, number of workdays missed (absenteeism)
and productivity losses while at work (presenteeism). To test
the overall influence of productivity costs on the ICER, the
analyses were performed without productivity losses.
Furthermore, probabilistic sensitivity analyses (PSAs) were
performed, to assess the overall uncertainty of the model. In
the PSA, a random draw from all parameter distributions was
taken simultaneously (instead of point estimates) to calculate
incremental costs and effects. This process was repeated 1000
times. The results from the PSA are presented in a cost-effec-
tiveness plane (CE-plane).
Results
Costs, effects and cost-effectiveness
Table 1 shows the discounted costs for the different treatment
options over a 10-year period, divided into various cost cate-
gories. Costs for the omalizumab arm also included costs from
SoC. Drug costs were highest for omalizumab. Drug costs per
4 weeks of treatment with omalizumab were €745, compared
with drug costs for SoC of only €32. In addition, administration
costs of €14 per injection were applicable for omalizumab.
Other healthcare costs did not differ much between treatment
options, and consisted primarily of costs from outpatient visits
and laboratory tests. Costs in other sectors (i.e. productivity
costs) constituted the largest share of the total costs for both
treatment options, but were lowest for omalizumab. The vast
majority of productivity costs (about 94%) related to presen-
teeism. Savings on indirect costs largely compensated for
increased drug costs. Total costs were highest for omalizumab;
over a 10-year time horizon, the per patient incremental costs
of omalizumab compared with SoC were €1613.
Survival was equal for omalizumab and SoC. Omalizumab
resulted in a higher number of QALYs. Compared with SoC,
incremental QALYs were 009 (Table 1). The corresponding
ICER of omalizumab compared with SoC was €17 502 per
QALY gained.
Sensitivity analyses
The tornado diagram presented in Figure 2 provides the
results of the one-way sensitivity analyses and shows those
factors that had the largest effect on the ICER. The most
important factor was the cost of the drug; a reduction in the
price of omalizumab by 20% would lead to dominance, with
health gains at lower costs. An increase in the price of omal-
izumab by 20% would double the ICER. Figure 2 also shows
that productivity costs played an important role in the value
of the ICER; the percentage of patients employed and the pro-
ductivity loss while at work (i.e. presenteeism) ranked second
and third in influencing the ICER. When productivity costs
were excluded from the analyses, the ICER increased to
€85 310 per QALY gained.
The CE-plane presented in Figure 3 shows the incremental
costs and effects of omalizumab compared with SoC from
1000 simulations of the PSA. As such, the CE-plane shows the
uncertainty around the estimates. Omalizumab was more
costly than SoC in 823% of simulations, depicted by the dots
above the horizontal axis. Incremental costs of omalizumab
compared with SoC varied between €7000 and €6000. Con-
cerning incremental effects, omalizumab was more effective
than SoC in all simulations, depicted by the dots on the right-
hand side of the vertical axis. As a result, most simulations
were in the northeast quadrant, implying that omalizumab
resulted in additional costs and additional effects. The average
ICER was similar to the results from the deterministic
analyses.
The cost-effectiveness acceptability curve in Figure 4 show
the probability that omalizumab would be considered cost-
effective for a given threshold (depicted on the x-axis). The
probability of being accepted increased as the threshold
increased. At a threshold of €80 000 per QALY (the implicit
upper threshold in the Netherlands), the probability that oma-
lizumab would be considered cost-effective was approximately
95%.
Discussion
In this study, the cost-effectiveness of omalizumab (on top of
SoC) compared with SoC and placebo in patients with CSU
was assessed for the Netherlands. Omalizumab was shown to
be more effective than SoC, but also more costly. The ICER
for omalizumab compared with SoC was €17 502 per QALY
gained.
Various reasons limit the transferability of cost-effectiveness
studies to other countries: epidemiological differences, differ-
ences in treatment guidelines, differences in the availability of
healthcare resources and differences in relative prices.23 There-
fore, pharmacoeconomic guidelines often recommend the use
of local data. The generalizability of the results to other coun-
tries from this study should thus be considered with caution.
The adaptation of an existing pharmacoeconomic model, pop-
ulated with local data and adapted to national pharmacoeco-
nomic guidelines, can be useful if clinical parameters in the
Table 1 Costs and effects for different treatment options over a
10-year time horizon
Omalizumab
Standard
of care
Total costs €27 670 €26 056
Total healthcare costs €11 676 €3811
Drug costs €9625 €1342
Drug administration costs €153 €0
Other healthcare costs €1898 €2469
Total costs in other sectors €15 994 €22 245
Incremental costs of omalizumab €1613
QALYs 784 775
Incremental effects of omalizumab 009
Discount rate effects: 15%; discount rate costs: 40%.
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model are not expected to differ between countries. This study
used an existing pharmacoeconomic model, which was devel-
oped for the U.K.8
One important difference between the Dutch and U.K.
models is the perspective that has to be taken in order to fol-
low pharmacoeconomic guidelines. Dutch pharmacoeconomic
guidelines prescribe the societal perspective (including pro-
ductivity losses), whereas a healthcare perspective has to be
adopted in the U.K. The inclusion of productivity losses in the
analyses has a major influence on the ICER, as was shown in
the sensitivity analyses. When productivity losses are not
included in the analyses, the differences between the two
models are much smaller.
The CSU 2015 guidelines of the Dutch Dermatologists Asso-
ciation present a stepped-care model for the treatment of
CSU.24 In the development of these CSU guidelines the
GRADE method was used to assess predefined outcome mea-
sures with regard to several systemic therapies, including dis-
ease activity, quality of life, adverse events, and complete and
partial clinical responses. The Dutch treatment guidelines for
CSU prescribe modern second-generation antihistamines in a
once-a-day conventional dosage to form the first line of CSU
therapy. If the symptoms persist after 4 weeks, the dosage of
the modern second-generation antihistamines should be
increased up to fourfold. If this regimen fails, addition of
montelukast and/or switching to another modern second-
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Cost omalizumab
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Productivity loss while at work
Cumulative relapse for urticaria free
Placebo 24-week efficacy RESPONSE
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Fig 2. One-way sensitivity analyses for omalizumab vs. standard of care. The vertical line represents the base-case incremental cost-effectiveness
ratio (ICER); the width of the bars represents the influence on the ICER of a 20% change in the parameter value.
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Fig 3. Cost-effectiveness plane for omalizumab vs. standard of care. Each dot represents the estimates for one simulation of the probabilistic
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generation antihistamine is recommended. If the symptoms
are still uncontrolled, omalizumab should be added to the
existing therapy. In the stepped-care model omalizumab is the
third-line CSU therapy. After omalizumab, patients with CSU
should receive an add-on therapy with more conventional sys-
temic immunomodulating agents like ciclosporin, methotrex-
ate, azathioprine, dapsone, mycophenolate mofetil or
ultraviolet B therapy. Short courses (maximum 10 days) of
oral corticosteroids may also be used at all times if demanded
by CSU exacerbations.
On the request of the Dutch guidelines committee, an inde-
pendent senior health economist reviewed the cost-effective-
ness model and its results to ensure the accuracy of the
adaptations and the outcomes of the model. The reviewer con-
cluded that the methodology was applied correctly. The results
of the review were published along with the adapted Dutch
treatment guidelines.25
One limitation of this study is that a comparison with the
third-line treatment ciclosporin was not possible, as currently
no data are available that compare omalizumab with ciclos-
porin. However, the comparison is highly relevant because
ciclosporin was the standard treatment alternative in daily
practice. Dutch pharmacoeconomic guidelines prescribe that
the alternative treatment in daily practice should be used as
the comparator in the pharmacoeconomic model. If data on
the relative effectiveness of omalizumab compared with ciclos-
porin become available, ciclosporin should be included in the
cost-effectiveness calculations as an additional comparator
treatment.
In most cases, CSU does not last for more than 5 years.26,27
However, to cover all patients with CSU in the cost-effective-
ness analyses, the time horizon was set at 10 years in this
study.
In the absence of a unit price for injections, the Dutch tariff
for a vaccination was used to represent the administration
costs of omalizumab. As injections are given in a hospital, this
tariff might underestimate the actual costs of administration.
In order to examine the impact of the cost of administration,
we calculated a scenario when these costs were doubled. This
assessment showed that these costs had a limited impact on
the ICER; the ICER would increase to €19 159 per QALY and
hence omalizumab would remain cost-effective under the
€20 000 per QALY threshold.
The sensitivity analyses showed that productivity costs have
a large influence on the ICER. The Dutch pharmacoeconomic
guidelines prescribe that the friction cost method should be
used to value productivity losses.9 In this method, productivity
costs are incurred only during the first period of absence, after
which an employee will be replaced.28 The friction period is
equal to 23 weeks of absence.20 Data were not available to
adopt the friction cost method in the model. However, in this
study the majority of productivity costs were related to pre-
senteeism (being less productive at work), which is not
affected by the methodology used to quantify productivity
costs. Although measuring presenteeism is difficult, the find-
ings do correspond with the clinical image of the disease
where patients are still able to go to their work, but are
impaired during their work.
In the one-way sensitivity analyses, parameter values were
increased and decreased by 20% to identify the influence of
individual parameters on the ICER. The 20% value was chosen
arbitrarily.
Various parameter values in the model were based on the
international ASSURE-CSU study, which aimed to assess the
burden of CSU.10 The study aimed to enrol about 100 patients
in seven countries. Data were available for 93 Dutch patients.
As these patients were divided into five health states, the num-
ber of patients per health state was limited, which is a short-
coming of the ASSURE-CSU study. As a result, uncertainty
around the point estimates for the parameters derived from
the ASSURE study was substantial. The effect of this was
shown in the relatively wide dispersion in the CE-plane. A lar-
ger sample would be needed to reduce the variation. As health
states do not deviate between treatments in the model (differ-
ences between treatments in the model are driven by transi-
tion probabilities), it was not necessary to study differences
between treatments in the ASSURE-CSU study. Data from other
countries could not be combined because of international dif-
ferences in healthcare financing, but the overall trends in data
were similar between countries.
In conclusion, this study showed that treatment of patients
with CSU with omalizumab was cost-effective, when the Dutch
implicit thresholds (ranging from €20 000 to €80 000 per
QALY) are considered. This study led to the establishment of
omalizumab as a third-line treatment in the guidelines for CSU.
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